Physician profile
Daxten L Pruter
NPI 1053866541
$1,938.99
in general payments reported to CMS, 2019-2025
15 companies · $230 in 2025
The $230 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $688 · 2022: $419 · 2024: $601 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $831.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $311.45 | 2021 | |
| Novo Nordisk INC | $233.09 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $126.33 | 2024 | Ingrezza |
| Tempus Ai, INC | $124.38 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $122.20 | 2025 | Austedo Xr |
| Averitas Pharma INC. | $122.12 | 2024 | Qutenza |
| Novartis Pharmaceuticals Corporation | $116.97 | 2024 | |
| Glaxosmithkline, LLC. | $114.02 | 2021 | |
| Urovant Sciences INC | $112.30 | 2022 | |
| Coloplast Corp | $111.37 | 2024 | |
| Edwards Lifesciences Corporation | $108.01 | 2025 | Sapien 3 Ultra Resilia |
| E.R. Squibb & Sons, L.L.C. | $99.64 | 2022 | |
| Idorsia Pharmaceuticals US INC | $97.50 | 2022 | |
| Esperion Therapeutics, INC. | $79.20 | 2021 | |
| Abbvie INC. | $60.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daxten Pruter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.